Search clinical trials for: Overweight participants

Total 16991 results

Eli Lilly and Company

Completed

A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program (SURMOUNT-3)

Obesity | Overweight

United States, Argentina, Brazil, Puerto Rico
Amgen

Completed

Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity

Obesity

United States
Eli Lilly and Company

Active, not recruiting

A Study of LY3541105 in Healthy and Overweight Participants

Healthy | Overweight

United States
Beijing QL Biopharmaceutical Co.,Ltd

Enrolling by invitation

A Study of ZT002 Injection in Participants With Overweight or Obesity

Overweight or Obesity

China
CorEvitas
Eli Lilly and Company

Withdrawn

The Purpose of This Registry Study is to Learn More About Metabolic Health: Approximately 15,000 Participants Who Are Overweight or Have Obesity With or Without Metabolic Diseases Are Expected to Participate in This Registry Study.

Metabolic Health
Eli Lilly and Company

Completed

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight (SURMOUNT-2)

Obesity | Overweight | Type 2 Diabetes

United States, Russian Federation, Taiwan, Argentina, Brazil, Japan, Puerto Rico, India
Zealand Pharma

Active, not recruiting

A Research Study Looking at the Safety of Multiple Doses of ZP8396 and How it Works in the Body of Healthy Participants

Overweight | Healthy Volunteers | Obese

Germany
Eli Lilly and Company

Completed

A Study of LY3841136 in Healthy and Overweight Participants

Healthy | Obesity

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Diabetes Prevention Program With or Without Hunger Training in Helping to Lower Breast Cancer Risk in Obese Participants

Obesity | Overweight | Ductal Breast Carcinoma In Situ | Deleterious BRCA1 Gene Mutation | Deleterious BRCA2 Gene Mutation | Premalignant Lesion

United States
Eli Lilly and Company

Active, not recruiting

A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities

Obesity | Overweight

China
Eli Lilly and Company

Active, not recruiting

A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese

Overweight

United States
Gasherbrum Bio, Inc

Active, not recruiting

A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants

Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide

Obesity

United States
Women's and Children's Hospital, Australia
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Optimising Protection for Pregnant Women and Infants With Maternal Vaccination (OPTIWIN)

Obesity

Australia
Eli Lilly and Company

Completed

A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN) (SURMOUNT-CN)

Obesity | Overweight | Metabolism and Nutrition Disorder

China
Cytoki Pharma
SGS Life Sciences, a division of SGS Belgium NV

Completed

A Phase 1 Study to Investigate Safety, Tolerability, and Pharmacokinetics of CK-0045 in Healthy Participants and Otherwise Healthy Participants With Obesity

Healthy

Belgium
Eli Lilly and Company

Completed

A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide

Obesity | Diabetes Mellitus, Type 2 | Overweight

United States
AstraZeneca

Completed

Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese

Healthy Participants

United States
Rhythm Pharmaceuticals, Inc.

Completed

Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity

Bardet Biedl Syndrome (BBS) | Alström Syndrome (AS)

United States, United Kingdom, France, Canada, Puerto Rico, Spain
Pfizer

Completed

Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity

Obesity

United States
Eli Lilly and Company

Completed

A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants

Healthy | Obese

United States
Radius Pharmaceuticals, Inc.

Terminated

A Study to Assess RAD011 (Cannabidiol Oral Solution) for the Treatment of Participants With Prader-Willi Syndrome (SCOUT-015)

Prader-Willi Syndrome

United States
Pfizer

Terminated

A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants

Healthy

United States
Eli Lilly and Company

Completed

A Study of LY3437943 in Participants Who Have Obesity or Are Overweight

Obesity | Overweight

United States, Puerto Rico
Eli Lilly and Company

Completed

A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities

Obesity | Overweight and Obesity

United States, Hungary, Canada, Puerto Rico
Sciwind Biosciences APAC CO Pty. Ltd.
Hangzhou Sciwind Biosciences Co., Ltd.

Completed

Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity

Obesity

Australia
Pfizer

Completed

A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy

Healthy Volunteer

United States
Rhythm Pharmaceuticals, Inc.

Completed

Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity

Obesity | Genetic Obesity | Obesity Due to Melanocortin 4 Receptor Deficiency

United States, United Kingdom, Germany, Netherlands, France, Canada, Greece, Israel, Spain
Rhythm Pharmaceuticals, Inc.

Completed

Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants

Overweight

United States
Eli Lilly and Company

Completed

A Study of LY3437943 in Chinese Participants With Obesity Or Overweight

Obesity | Overweight

China
Eli Lilly and Company

Completed

A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease (SURMOUNT-J)

Obesity

Japan
Rhythm Pharmaceuticals, Inc.

Completed

Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome

Prader-Willi Syndrome

United States
Eli Lilly and Company

Completed

A Study of LY3457263 in Obese Participants

Obesity | Overweight

United States
Eli Lilly and Company

Completed

A Study of LY3305677 in Participants With Obesity Or Overweight

Obesity | Overweight

United States
Radius Pharmaceuticals, Inc.
Benuvia Therapeutics Inc.

Terminated

A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Participants With Prader-Willi Syndrome

Prader-Willi Syndrome

United States
Laouani Aicha
Faculty of Medicine, Sousse; Centre Hôpital Universitaire Farhat Hached; University... and other collaborators

Completed

Safety and Efficacy of Medicinal Plant Extract in Overweight and Obese Participants.

Obesity | Overweight

Tunisia
Eli Lilly and Company

Completed

A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants

Obesity

United States
Medical University of Bialystok

Completed

Genes Variability in Obesity and Normal Body Weight Patients.

Obesity | Obesity, Visceral

Poland
MedImmune LLC

Completed

A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Participants With Type 2 Diabetes Mellitus

Obesity | Diabetes Mellitus, Type II

United Kingdom
Zealand Pharma

Completed

A First-in-human Study Looking at the Safety of ZP8396 and How it Works in the Body of Healthy Trial Participants

Overweight | Healthy Volunteers

Germany
Eli Lilly and Company

Completed

A Study of LY3502970 in Healthy Overweight and Obese Participants

Healthy | Obese

United States
Carmot Therapeutics, Inc.

Active, not recruiting

A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus

Obesity | Type2 Diabetes

United States, Mexico
Bristol-Myers Squibb

Withdrawn

A Study to Evaluate the Drug Levels and Safety of Pegbelfermin in Healthy Overweight and Obese Chinese and Korean Participants

Healthy Participants

China, Korea, Republic of
Pfizer

Completed

STUDY TO COMPARE PHARMACOKINETICS (PK) OF SINGLE ORAL DOSES OF DIFFERENT PF-06882961 FORMULATIONS IN PARTICIPANTS WHO ARE OVERWEIGHT OR HAVE OBESITY

Overweight and/or Obesity

Belgium
Goldfinch Bio, Inc.

Completed

First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes

Kidney Diseases | Diabetes Mellitus | Endocrine System Diseases | Diabetes Complications | Diabetic Nephropathies

United States
Bristol-Myers Squibb

Completed

Relative Levels of BMS-986036 in Blood Plasma in Healthy, Overweight, and Obese Participants Following Subcutaneous Administration Via Auto-injector Versus Pre-filled Syringe

Healthy Participants

United States
Forma Therapeutics, Inc.
ProSciento, Inc.

Terminated

A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis

Nonalcoholic Steatohepatitis (NASH) | Overweight or Obesity

United States
University of Alberta
W. Garfield Weston Foundation

Completed

Fecal Microbial Transplantation and Fiber Supplementation in Participants With Obesity and Metabolic Syndrome.

Obesity | Metabolic Syndrome

Canada
MedImmune LLC

Completed

A Study to Assess Safety, Tolerability, and Pharmacokinetics of MEDI0382 in Non-diabetic Obese Participants

Obesity

United States
Eli Lilly and Company

Completed

A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia

Dyslipidemias

United States

3

Subscribe